2021 Essex County Council election

Kurome Therapeutics Announces Oral and Poster Presentations on Dual IRAK1/4 Inhibitors at American Society of Hematology Annual Meeting

Retrieved on: 
Tuesday, December 6, 2022
Oncology, Health, Research, Pharmaceutical, Science, Biotechnology, Therapy, Exposition, Ecklonia kurome, BS, Cincinnati Children's Hospital Medical Center, National Center for Advancing Translational Sciences, Doctor of Philosophy, Pharmacology, Society, 2021 Essex County Council election, Smoking and Health: Report of the Advisory Committee to the Surgeon General of the United States, Cancer, Acute myeloid leukemia, MS, Lead, IRAK1, AML, Myelodysplastic syndrome, National Institutes of Health, MDS, Drug resistance, ASH, Pharmaceutical industry, Vaccine

Kurome Therapeutics, Inc., a late pre clinical stage biotech company developing novel IRAK1/4 inhibitors for oncology indications, today announced two abstracts have been accepted for oral and poster presentations at the 64th American Society of Hematology (ASH) Annual Meeting and Exposition, to be held December 9-13, 2022, in New Orleans.

Key Points: 
  • Kurome Therapeutics, Inc., a late pre clinical stage biotech company developing novel IRAK1/4 inhibitors for oncology indications, today announced two abstracts have been accepted for oral and poster presentations at the 64th American Society of Hematology (ASH) Annual Meeting and Exposition, to be held December 9-13, 2022, in New Orleans.
  • The presentations highlight preclinical data supporting the importance of inhibiting both IRAK1 and IRAK4 in Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS).
  • Kurome is developing a series of potent IRAK1/4 and panFLT3 inhibitors that work by targeting key cancer survival pathways.
  • The companys first to market indications will be Acute Myeloid Leukemia (AML) and high-risk MDS.

Lightbits Labs Awarded Patent

Retrieved on: 
Tuesday, December 6, 2022
Internet, Data Management, Other Technology, Technology, Software, OpenStack, VMware, 2021 Essex County Council election, Database, Muli, Patent, Invention, NVM Express, Computer data storage

Lightbits , the first software-defined and architected for NVMe/TCP data platform for any cloud, today announced it has been assigned a patent (11,513,729) for distributed write buffer for storage systems.

Key Points: 
  • Lightbits , the first software-defined and architected for NVMe/TCP data platform for any cloud, today announced it has been assigned a patent (11,513,729) for distributed write buffer for storage systems.
  • The innovation described in this patent takes Lightbits IFM feature a step further by distributing the reads and writes to all nodes in the clusters persistent memory to further improve the endurance of NVMe flash and provide faster response to the application I/Os.
  • Customers use Lightbits to enable fast, reliable, and secure cloud services and run cloud-native applications with their existing orchestration environments OpenStack , VMware , and Kubernetes .
  • To read the patent abstracts and full detail go to: https://patents.justia.com/assignee/lightbits-labs-ltd
    For more information on the Lightbits leadership team, go to: https://www.lightbitslabs.com/company/

Dr. Sham Dholakia joins GEn1E Lifesciences as Chief Medical Officer, as it further scales its AI/ML platform, portfolio and partnerships

Retrieved on: 
Wednesday, December 14, 2022
Immunology, University of Oxford, Acute respiratory distress syndrome, PALO, Pharmacology, 2021 Essex County Council election, Patient, Sham, Knowledge, HIV disease progression rates, AI, Nextgen, CMO, Data analysis, Inflammation, Growth, University, Machine learning, Imperial College London, Cybook Gen1, Scientific Research Publishing, Transplant, Algorithm, Pharmaceutical industry, Medical device

PALO ALTO, Calif., Dec. 14, 2022 /PRNewswire/ -- A clinical-stage, next-generation techbio company, developing multitarget, novel and targeted immunomodulatory therapies for rare and inflammatory diseases, today announces the appointment of Dr. Sham Dholakia as the Chief Medical Officer.

Key Points: 
  • GEn1E has created a differentiated "Platform-in-a-Mechanism" model that uses AI and Machine Learning across the entire end-to-end drug development cycle.
  • Dr. Sham Dholakia, an accomplished transplant surgeon trained at the University of Oxford, joins GEn1E with more than 15 years of clinical experience in the hospital, pharmaceutical and diagnostic industries.
  • Dr. Sham Dholakia, incoming CMO of GEn1E commented "Uncontrolled inflammation is the core of disease progression and poor clinical outcomes.
  • GEn1E Lifesciences is based in Palo Alto, CA, with a laboratory in Mountain View, CA.

ELECTRIC VEHICLES REACH THREE MILLION MILESTONE AS POWER2DRIVE EUROPE STRENGTHENS ITS STATUS AS A LEADING EXHIBITION WITH ITS TEST DRIVES, CONFERENCE AND NEW AWARD

Retrieved on: 
Tuesday, December 13, 2022
Electrification, Light electric vehicle, ICM, AWARD, Conference, Projection, Union, Acceleration, CPO, 2021 Essex County Council election, Bidirectional, Federal Motor Vehicle Safety Standards, AutoNation, EV, Wind, Research, Interaction, BEV, Motor vehicle, Bundeswehr, EMP, European, Exhibition, Carbon, Organization, Pharmaceutical industry, Rail transport, Online shopping, EU

The e-mobility industry is booming, with one million e-cars (battery electric vehicles, BEV) expected to be registered in Germany by the end of the year.

Key Points: 
  • The e-mobility industry is booming, with one million e-cars (battery electric vehicles, BEV) expected to be registered in Germany by the end of the year.
  • Two test drives in 2023: eCar and lightEV
    The Power2Drive Europe exhibition will shine the spotlight on charging systems, electric vehicles, traction batteries and mobility services.
  • Suppliers of electric passenger cars and commercial vehicles interested in inviting Power2Drive visitors to test drive their vehicles can register here .
  • Power2Drive Europe is part of The smarter E Europe the continent's innovation hub for the new worlds of energy and mobility.

ELECTRIC VEHICLES REACH THREE MILLION MILESTONE AS POWER2DRIVE EUROPE STRENGTHENS ITS STATUS AS A LEADING EXHIBITION WITH ITS TEST DRIVES, CONFERENCE AND NEW AWARD

Retrieved on: 
Tuesday, December 13, 2022
Electrification, Light electric vehicle, ICM, AWARD, Conference, Projection, Union, Acceleration, CPO, 2021 Essex County Council election, Bidirectional, Federal Motor Vehicle Safety Standards, AutoNation, EV, Wind, Research, Interaction, BEV, Motor vehicle, Bundeswehr, EMP, European, Exhibition, Carbon, Organization, Pharmaceutical industry, Rail transport, Online shopping, EU

The e-mobility industry is booming, with one million e-cars (battery electric vehicles, BEV) expected to be registered in Germany by the end of the year.

Key Points: 
  • The e-mobility industry is booming, with one million e-cars (battery electric vehicles, BEV) expected to be registered in Germany by the end of the year.
  • Two test drives in 2023: eCar and lightEV
    The Power2Drive Europe exhibition will shine the spotlight on charging systems, electric vehicles, traction batteries and mobility services.
  • Suppliers of electric passenger cars and commercial vehicles interested in inviting Power2Drive visitors to test drive their vehicles can register here .
  • Power2Drive Europe is part of The smarter E Europe the continent's innovation hub for the new worlds of energy and mobility.

Invitae Releases Data Use Transparency Report, Demonstrating the Impact of Patient Data on Genetic Research

Retrieved on: 
Wednesday, December 7, 2022
Security (finance), Half-light: Collected Poems 1965–2016, Genetics, Culture, Development, Publishing, Science, McGraw, 2021 Essex County Council election, Patient, Prevalence, ClinVar, Foundation for the National Institutes of Health, Forensic Science International: Genetics, Research, Precision medicine, NYSE, Medicine, Genomics, Growth, Clinical trial, SAN, Database, Legislation, Genetic testing, Medical imaging, Pharmaceutical industry, Medical device, Invitae

SAN FRANCISCO, Dec. 7, 2022 /PRNewswire/ -- Invitae (NYSE: NVTA), a leading medical genetics company, today announced the release of its Data Use Transparency and Impact Report, which details how the company has used de-identified patient data to advance precision medicine. While many companies collect patient data, they do not disclose how this data is being used. Invitae is leading the industry by publishing this first-of-its-kind report on how it used de-identified patient data for secondary data research in 2021. 

Key Points: 
  • While many companies collect patient data, they do not disclose how this data is being used.
  • Invitae is leading the industry by publishing this first-of-its-kind report on how it used de-identified patient data for secondary data research in 2021.
  • Unlike most companies, Invitae offers patients a choice on whether or not to allow access to their de-identified data for research.
  • Further showcasing the importance of sharing patient data, Invitae recently reached a milestone of more than 1 million ClinVar submissions .

BostonGene Announces Presentations at the 64th American Society of Hematology (ASH) Annual Meeting & Exposition

Retrieved on: 
Friday, December 2, 2022
Oncology, Health, Technology, Artificial Intelligence, Pharmaceutical, Biotechnology, Medicine, Standard of care, Memorial Sloan Kettering Cancer Center, Economics, DLBCL, Research, Cancer, RNA, WES, Patient, Neoplasm, Biomarker, 2021 Essex County Council election, RNA-Seq, Medical imaging

Time and Location: Monday, December 12 | 6:00 PM-8:00 PM, Hall D

Key Points: 
  • Time and Location: Monday, December 12 | 6:00 PM-8:00 PM, Hall D
    Research conducted by Memorial Sloan Kettering Cancer Center and BostonGene.
  • In addition to the poster presentations, the abstracts have been published online in the November supplemental issue of Blood .
  • BostonGene Tumor Portrait Tests reveal key drivers of each tumor, including immune microenvironment properties, actionable mutations, biomarkers of response to diverse therapies, and recommended therapies.
  • Through these comprehensive analyses, BostonGene Tumor Portrait Tests generate a personalized roadmap for therapeutic decision-making for each cancer patient.

Guardant Health to Showcase New Data at San Antonio Breast Cancer Symposium 2022 Demonstrating Utility of Its Blood Tests for Advanced-stage Breast Cancer Patients

Retrieved on: 
Thursday, December 1, 2022
Oncology, Health, Genetics, Research, Science, Biotechnology, Result, Financial condition report, Incidence, Health, 2021 Essex County Council election, Helmy Eltoukhy, Patient, Analysis, Biomarker, Annual report, Security (finance), GATA3, Data, Breast cancer, GH, Medical imaging

Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, announced today that new data from its portfolio of blood tests will be presented at the 2022 San Antonio Breast Cancer Symposium, December 6-10 in San Antonio, Texas.

Key Points: 
  • Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, announced today that new data from its portfolio of blood tests will be presented at the 2022 San Antonio Breast Cancer Symposium, December 6-10 in San Antonio, Texas.
  • We look forward to sharing new data at the San Antonio Breast Cancer Symposium demonstrating the utility of our blood tests to increase the understanding of potential biomarker targets and the mechanisms of molecular response in patients with advanced breast cancer, said Helmy Eltoukhy, Guardant Health co-CEO.
  • Guardant Health is a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary tests, vast data sets and advanced analytics.
  • Guardant Health has commercially launched Guardant360, Guardant360 CDx, Guardant360 TissueNext, Guardant360 Response, and GuardantOMNI tests for advanced stage cancer patients, and Guardant Reveal for early-stage cancer patients.

Theralink® Technologies Accepted to Present Two Posters at the Upcoming San Antonio Breast Cancer Symposium

Retrieved on: 
Thursday, December 1, 2022
HER2, OTC, Head, 2021 Essex County Council election, Lung, Patient, Oncology, CLIA, Liver, Prostate, Drug development, Security (finance), Neck, Precision medicine, Ultra-low latency direct market access, LDT, Breast cancer, CAP, FDA, Medical imaging

GOLDEN, Colo., Dec. 1, 2022 /PRNewswire/ -- Theralink Technologies (OTC: THER) ("Theralink" or the "Company"), a precision oncology company with a novel quantitative protein and phosphoprotein-based assay for breast cancer, today announced the acceptance of two poster presentations evaluating the potential use and utility of its novel RPPA (Reverse Phase Protein Array) technology at the San Antonio Breast Cancer Symposium (SABCS) 2022.

Key Points: 
  • Mick Ruxin M.D., CEO of Theralink Technologies stated, "We are so pleased to have multiple poster presentations accepted at SABCS this year.
  • During our presentations we will highlight the potential of our innovative RPPA-based technology for clinical molecular profiling of breast cancer patients.
  • The Theralink Assay for Advanced Breast Cancer can provide additional levels of quantified clarity for patients who need it the most."
  • The Theralink management team welcomes the opportunity to meet with you in-person in San Antonio at SABCS 2022.

COTA, Inc. Announces Seven Upcoming Poster Presentations at the 2022 American Society of Hematology Annual Meeting

Retrieved on: 
Thursday, December 1, 2022
Multiple myeloma, B-cell lymphoma, AML, 2021 Essex County Council election, Food, University, CLL, Cancer, Acute myeloid leukemia, Partnership, MM, Patient, Excellence, Hematological Cancer Research Investment and Education Act, Society, RWD, ASH, COTA, Physical Sciences-Oncology Centers, Research, Chronic lymphocytic leukemia, Health care, DLBCL, RRMM, Lymphatic system, Pharmaceutical industry, Medical imaging, Medicine

NEW YORK, Dec. 1, 2022 /PRNewswire/ -- COTA, Inc. ,an oncology real-world data and analytics company, announced that seven abstracts leveraging COTA's oncology real-world data (RWD) will be presented at the 64th American Society of Hematology (ASH) Annual Meeting taking place in New Orleans, Louisiana, from December 1013, 2022.

Key Points: 
  • NEW YORK, Dec. 1, 2022 /PRNewswire/ -- COTA, Inc. ,an oncology real-world data and analytics company, announced that seven abstracts leveraging COTA's oncology real-world data (RWD) will be presented at the 64th American Society of Hematology (ASH) Annual Meeting taking place in New Orleans, Louisiana, from December 1013, 2022.
  • "There is a continuous need to better understand how emerging therapies are impacting patients in everyday healthcare settings," said C.K.
  • COTA co-authored three of the seven abstracts accepted for poster presentation at the ASH conference.
  • The accepted poster presentations leveraging COTA's oncology real-world data include: